NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES

$271,490P50FY2013CANIH

University Of California, San Francisco, San Francisco CA

Investigators

Linked publications, trials & patents

Paper 39560080 Paper 39558036 Paper 39468647 Paper 39417102 Paper 39387520 Paper 39251601 Paper 39028616 Paper 38916140 Paper 38834748 Paper 38766059 Paper 38760638 Paper 38760585 Paper 38509407 Paper 38466631 Paper 38451815 Paper 38260701 Paper 38260689 Paper 38254844 Paper 38242087 Paper 38234734 Paper 38221978 Paper 38221889 Paper 38141254 Paper 38079020 Paper 37978951 Paper 37904942 Paper 37821623 Paper 37758193 Paper 37660254 Paper 37611371 Paper 37609137 Paper 37595256 Paper 37546798 Paper 37503127 Paper 37458412 Paper 37436963 Paper 37404460 Paper 37337720 Paper 37138086 Paper 37104042 Paper 36997627 Paper 36993741 Paper 36856115 Paper 36778397 Paper 36729132 Paper 36610073 Paper 36599113 Paper 36522672 Paper 36348337 Paper 36307860 Paper 36264168 Paper 36239925 Paper 36201590 Paper 36130485 Paper 36127421 Paper 36114166 Paper 36007439 Paper 35990705 Paper 35972367 Paper 35945463 Paper 35915160 Paper 35759011 Paper 35716311 Paper 35703914 Paper 35679032 Paper 35649412 Paper 35587512 Paper 35587280 Paper 35550063 Paper 35544642 Paper 35534562 Paper 35511927 Paper 35395677 Paper 35392283 Paper 35371527 Paper 35334192 Paper 35325218 Paper 35287169 Paper 35202840 Paper 35189960 Paper 35140201 Paper 35090034 Paper 35084981 Paper 35084939 Paper 35063085 Paper 35063012 Paper 34910220 Paper 34882581 Paper 34825267 Paper 34821426 Paper 34801162 Trial NCT05851378 Trial NCT05557292 Trial NCT04540107 Trial NCT04019002 Trial NCT03739411 Trial NCT00823459 Trial NCT00293423 Patent 9683996 Patent 9145462

Abstract

instnjctions):Gliomas are aggressive brain tumors that affect children. Current treatment of high-grade glioma, most ofteninvolving surgery, radiation, and cytotoxic chemotherapy, only extend median survival of affected children to14 months, and results in significant morbidity. Low-grade glioma, that cannot be completely resected aretreated with radiation, typically after failure of chemotherapy approaches, with significant resulting neuro-cognitive and developmental risks. This project addresses a specific oncogene alteration, BRAF^^¿^occurring in as many as 14% of pediatric high-grade glioma. For certain subtypes of pediatric glioma thefrequency of BRAF''^¿¿^ is much higher (66% in pleomorphic xanthoastrocytoma). Inhibitors that specificallytarget BRAF^(R)¿¿^ have been developed and have shown remarkable efficacy against melanomas that harborthis mutation. One such inhibitor, vemurafenib, has now been FDA-approved for melanoma, and is underinvestigation for treating a number of other BRAF^(R)

View original record on NIH RePORTER →